A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

200431 citationsJournal Article

Authors

Jean-Marc Ferrero · Centre Antoine Lacassagne

Cyril Foa · Centre Antoine Lacassagne

Simon Thézenas · CEA Valduc

Philippe Ronchin · Centre Azuréen de Cancérologie

Frédéric Peyrade · Centre Antoine Lacassagne

B. Valenza · Centre Hospitalier de la Dracénie

G Lesbats

Abstract

Weekly docetaxel at a dosage of 40 mg/m(2) is a well-tolerated treatment, which has very promising activity on the reduction of PSA in metastatic HRPC. A large phase III study is underway.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer Treatment and Pharmacology Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Oncology

Volume 66, Issue 4, pp. 281-287

DOI: 10.1159/000078328

Field-Weighted Citation Impact: 4.42